Foghorn Therapeutics Inc (FHTX)
Healthcare
Biotechnology
4.50 $
-4.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Foghorn Therapeutics Inc (FHTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 46.7% of the shares are freely tradable; institutional investors hold 76.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
76.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
17.9%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
46.7%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.4%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
59Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Flagship Ventures Management, Inc. | 21.59 | 12,674,120 | +0.0 | 03/31/2026 |
| FMR Inc | 10.30 | 6,047,198 | +12.1 | 03/31/2026 |
| Bvf Inc | 9.95 | 5,842,000 | +10.2 | 03/31/2026 |
| Deerfield Management Co | 7.48 | 4,394,367 | +20.4 | 03/31/2026 |
| BlackRock Inc | 4.03 | 2,364,866 | +0.6 | 03/31/2026 |
| Vanguard Group Inc | 3.29 | 1,928,992 | +1.6 | 12/31/2025 |
| Euclidean Capital LLC | 2.68 | 1,573,761 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.55 | 1,495,089 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 4.64 | 2,722,440 | +0.1 | 04/30/2026 |
| Fidelity Growth Company Fund | 3.13 | 1,836,447 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.